Around 50,000 people, across a number of countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the company said on Saturday in a press release.
"The third phase of clinical trials of the inactivated CNBG vaccine against COVID-19 is significantly accelerating, and clinical trials are already underway in several countries, including Bahrain, UAE, Morocco, Peru, Argentina, with about 50,000 people participating," the CNGB said.
Media reported in July that phase 3 trial of CNBG's vaccine will also be held in Uzbekistan, and Pakistan has expressed interest in conducting clinical trials as well.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Seeks Approval For Phase 3 Trial Of Intranasal Shots As Boosters Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today Chinese Vaccines Show Safety But Lack Data: WHO Experts Video: Leopard Spotted Crossing Road In Bengaluru's Electronic City Arvind Kejriwal Resigns After Choosing Atishi As His Replacement AAP Asks Its Rajya Sabha MP Swati Maliwal To Quit Over Atishi Remarks "We Will Not Spare You": Nitin Gadkari Warns Contractors Over Poor Roads Kangana Ranaut Says Sold Mumbai Property After 'Emergency' Postponed China Landlord Tries To Evict Cancer-Stricken Tenant Over Property Value Track Latest News Live on NDTV.com and get news updates from India and around the world.